BEBT-607 is a highly potent KRAS G12C inhibitor, which is mainly used for the treatment of advanced or metastatic solid tumors such as non-small cell lung, colorectal, and pancreatic cancers with KRAS G12C mutations. In May 2021, the FDA approved the world's first KRAS G12C inhibitor, Sotorasib (AMG-510), for the treatment of non-small cell lung cancer with KRAS G12C mutations. Up to now, no same-target inhibitors have been approved for marketing in China. Preclinical animal model studies have shown that BEBT-607 can induce tumor regression in KRAS G12C-mutant tumor models. The Company's BEBT-607 has initiated a Phase I clinical trial in September 2023 and one subject has been enrolled in the Phase I trial.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号